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S U M M A R Y
Hantavirus pulmonary syndrome (HPS) is an often fatal rodent-borne zoonosis caused by any of at least
20 hantavirus genotypes distributed throughout the Americas. Although HPS has been documented in
several bordering countries, it has not been reported in Colombia. Here we report seroconversion to a
hantavirus in paired samples from a hospitalized patient with symptoms compatible with HPS from
Monterı´a, Co´rdoba Department, north-western Colombia. Tests for regionally endemic agents including
Plasmodium, Leptospira, Salmonella, dengue virus, Brucella, Rickettsia, human immunodeﬁciency virus
and hepatitis viruses were negative. Because the patient was enrolled in a clinical trial for hemorrhagic
fevers conducted by the University of Co´rdoba, serum samples were collected on admission and at
discharge. Testing using Sin Nombre virus ELISA showed IgG and IgM seroconversion between samples.
The eventual ﬁnding of this ﬁrst clinical case of hantavirus infection in Colombia is consistent with the
high prevalence of hantavirus antibodies in humans in the region and the likely exposure of the patient
to rodents. The clinical presentation was similar to that found in neighbouring Panama.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Hantavirus pulmonary syndrome (HPS) is an often fatal rodent-
borne zoonosis caused by any of at least 20 hantavirus genotypes
distributed throughout the Americas. The disease was ﬁrst
identiﬁed in the USA where the newly described etiological agent,
Sin Nombre virus (SNV), has caused approximately 600 cases
with a fatality rate of 36%.1 Although HPS is documented in
several bordering countries, it has not been reported in Colombia.
In 2004, we detected IgG antibodies to SNV by ELISA in 14% of
serum samples from 88 rural volunteers in north-western
Colombia.2 In 2013, we detected IgG antibodies to Maciel or
Araraquara hantaviruses in 8.4% of 286 agricultural workers in
Co´rdoba Department.3 These prevalences are much higher than
those found in serosurveys in North America and suggest that
rural workers in north-western Colombia are frequently exposed* Corresponding author. Tel.: +57 47 560710; fax: +57 47 860064/65.
E-mail address: mattarsalim@hotmail.com (S. Mattar).
http://dx.doi.org/10.1016/j.ijid.2014.03.1396
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).to one or more hantaviruses.2–5 Nevertheless, no HPS cases had
been reported in Colombia.
2. Methods
In May 2013, a 26-year-old man from Monterı´a, Colombia
(Figure 1) was admitted to the emergency ward (San Jero´nimo
Hospital, Monterı´a) complaining of fever, headache, arthralgia,
myalgia, asthenia, malaise, and dyspnoea of 7-day duration.
He was tested for regionally endemic agents, Plasmodium,
Leptospira, Salmonella, dengue virus, Brucella, Rickettsia, human
immunodeﬁciency virus and hepatitis viruses. Because the
patient was enrolled in a clinical trial for hemorrhagic fevers
conducted by the University of Co´rdoba, serum samples were
collected on admission and at discharge. These serum samples
were tested by ELISA for antibodies reactive to SNV. The SNV
ELISA detects (cross-reacts with), but does not distinguish
between all known hantaviruses hosted by New World cricetid
rodents.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Map of South America showing the location of the city of Monterı´a, within
Co´rdoba Department, Colombia. Note the proximity to Panama.
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The patient lived in a rural natural habitat bordering cultivated
areas where people live alongside rodents and in poor sanitation
conditions. On admission, he was febrile (40 8C) and had a heart
rate of 76 beats/min and respiratory rate of 23 breaths/min. He had
icteric sclera, no lymphadenopathy, normal cardiac and pulmonaryTable 1
Potential etiological agents evaluated in a hantavirus pulmonary syndrome patient in 
Etiological agent Diagnostic method Result in acute
phase sample
Plasmodium sp Blood smear Negative for
parasitic forms
Leptospira sp MATa,b <1:100 
Salmonella sp Blood culture Negative 
Dengue virus IgM/Ns1 antigen Negative/negativ
Brucella sp Rose Bengal test Negative 
Rickettsia sp R. rickettsii/R. typhi
IFA IgG test, Focus
Diagnostics1a
<1:64/<1:64 
HIV ELISA Negative 
Hepatitis B virus HBsAg Negative 
Hantavirus ELISA IgM/IgGc 0.74/0.5 
MAT, microscopic agglutination test; IFA, immunoﬂuorescence antibody test; HBsAg, h
a Positive cut-off values: Leptospira MAT titre 1:100; Rickettsia IFA IgG titre 1:64
b ELISA Leptospira-IgM was also negative.
c Sin Nombre virus (SNV) ELISA IgM and IgG optical density (1.10, positive; <0.9, auscultation ﬁndings, painful splenomegaly, no rash, and a normal
neurological examination. A chest X-ray was normal. Pancytopenia
and hyperbilirubinemia were seen on haematological analysis.
Tests for regionally endemic agents in acute phase samples were
all negative (Table 1). The patient remained febrile for 3 days; he
was discharged on day 5 without a deﬁnitive diagnosis. ELISA
testing of the stored admission and discharge sera showed IgG and
IgM seroconversion to SNV. Tests for Leptospira, dengue virus,
Brucella and Rickettsia repeated on convalescent samples were
negative (Table 1).
4. Discussion
We did not ﬁnd it unusual that the case patient did not have
pulmonary oedema and only had a mild respiratory symptoms.
In a study done in bordering Panama, 21% of diagnosed HPS
patients did not show pulmonary oedema and 44% had mild HPS
with mild oedema but no respiratory insufﬁciency.6 The
investigators in Panama described three categories of hantavirus
infection: hantavirus fever (absence of dyspnoea, normal chest
X-ray, not requiring oxygen therapy), mild HPS (occasional or no
dyspnoea, abnormal chest X-ray), and moderate to severe HPS
(marked dyspnoea, abnormal chest X-ray, mechanical ventila-
tion required).6
The present serologically conﬁrmed HPS case is compatible
with hantavirus fever, as described above. In Colombia we have
observed other cases that are compatible with hantavirus fever,
but none have been conﬁrmed serologically. The rodents,
Zygodontomys brevicauda (reservoir of Calabazo virus in Panama)
and Oligoryzomys fulvescens (reservoir of Choclo virus, a known
agent of HPS in Panama), are also found in adjacent Colombia,7
including Co´rdoba. In 2011, investigators from Antioquia Depart-
ment (adjacent to Co´rdoba) found 14% of sampled Z. brevicauda to
be antibody-positive to SNV and Maciel viruses.4 Sequencing of
PCR amplicons from their lung tissue revealed a virus closely
related to Calabazo virus from Panama.4 This is the only report of
the genetic characterization of a hantavirus in rodents in Colombia.
Conﬁrmation of the case we describe was in accordance with
one US Centers for Disease Control and Prevention laboratory
criterion for the diagnosis of HPS – the detection of hantavirus-
speciﬁc IgM or rising titres of hantavirus-speciﬁc IgG.8 Neverthe-
less, hantavirus infection in humans in Colombia has not been
diagnosed by culture or molecular techniques. The eventual
ﬁnding of this ﬁrst clinical case of hantavirus infection in
Colombia is consistent with the high prevalence of hantavirus
antibodies in humans in the region and the likely exposure ofnorth-western Colombia
Result in convalescent
phase sample
Interpretation
Not performed Infection ruled out
<1:100 Without seroconversion
Not performed Infection ruled out
e Negative/not
performed
Infection ruled out
Negative Infection ruled out
<1:64/<1:64 Without seroconversion
Not performed Infection ruled out
Not performed Infection ruled out
12.6/3.5 Positive seroconversion
epatitis B surface antigen.
.
negative).
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similar to that found in neighbouring Panama.6 Finally, although
there is strong evidence of a broad geographic distribution of HPS
in the Americas and in neighbouring countries,2–5,9 a high
prevalence of hantavirus infection in local rodent populations,
and associated risk factors for HPS (exposure to rural rodents), the
apparent incidence of HPS in Colombia is low. One reason for this
disparity is likely poor surveillance within Colombia. It is also
possible that the strain of virus infecting humans in Colombia is
relatively benign and only rarely causes symptomatic disease.
The demonstration of HPS in Colombia is important information
for Colombian public health and medical personnel; this case
report should help physicians to suspect and diagnose HPS.
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